M
Mario E. Lacouture
Researcher at Memorial Sloan Kettering Cancer Center
Publications - 423
Citations - 20145
Mario E. Lacouture is an academic researcher from Memorial Sloan Kettering Cancer Center. The author has contributed to research in topics: Cancer & Rash. The author has an hindex of 68, co-authored 380 publications receiving 15894 citations. Previous affiliations of Mario E. Lacouture include Brigham and Women's Hospital & University of Chicago.
Papers
More filters
Journal ArticleDOI
Managing toxicities associated with immune checkpoint inhibitors: Consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group
Igor Puzanov,Adi Diab,K. Abdallah,Clifton O. Bingham,C. Brogdon,Ramona Dadu,Lamya Hamad,Sang Taek Kim,Mario E. Lacouture,Nicole R. LeBoeuf,D. Lenihan,C. Onofrei,Vickie R. Shannon,Rajeev Sharma,Ann W. Silk,Dimitra Skondra,Maria E. Suarez-Almazor,Yinghong Wang,K. Wiley,Howard L. Kaufman,Marc S. Ernstoff +20 more
TL;DR: A multidisciplinary Toxicity Management Working Group met for a full-day workshop to develop recommendations to standardize management of immune-related adverse events, and presents their consensus recommendations on managing toxicities associated with immune checkpoint inhibitor therapy.
Journal ArticleDOI
Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies
Jarushka Naidoo,David B. Page,Bob T. Li,L. C. Connell,Katja Schindler,Mario E. Lacouture,Mario E. Lacouture,Michael A. Postow,Michael A. Postow,Jedd D. Wolchok,Jedd D. Wolchok +10 more
TL;DR: Clinical studies investigating single-agent anti-PD-1/PD-L1 therapy and trials of combination approaches with other standard anticancer therapies, in multiple tumor types are reviewed and the key adverse events reported in these studies are summarized.
Journal ArticleDOI
Mechanisms of cutaneous toxicities to EGFR inhibitors.
TL;DR: There is an urgent need for an improved understanding of these toxicities to develop adequate staging systems and mechanistically driven therapies, and to ensure quality of life and consistent antineoplastic therapy.
Journal ArticleDOI
Skin Toxicity Evaluation Protocol With Panitumumab (STEPP), a Phase II, Open-Label, Randomized Trial Evaluating the Impact of a Pre-Emptive Skin Treatment Regimen on Skin Toxicities and Quality of Life in Patients With Metastatic Colorectal Cancer
Mario E. Lacouture,Edith P. Mitchell,Bilal Piperdi,Madhavan V. Pillai,Heather Shearer,Nicholas Iannotti,Feng Xu,M. Yassine +7 more
TL;DR: The incidence of specific >or= grade 2 skin toxicities during the 6-week skin treatment period was reduced by more than 50% in the pre-emptive group compared with the reactive group, and the pre.emptive skin treatment regimen was well tolerated.
Journal ArticleDOI
Management of Immunotherapy-Related Toxicities, Version 1.2019.
John A. Thompson,Bryan J. Schneider,Julie R. Brahmer,Stephanie Andrews,Philippe Armand,Shailender Bhatia,Lihua E. Budde,Luciano J. Costa,Marianne Davies,David Dunnington,Marc S. Ernstoff,Matthew J. Frigault,Brianna Hoffner,Christopher J. Hoimes,Mario E. Lacouture,Frederick L. Locke,Matthew A. Lunning,Nisha Mohindra,Jarushka Naidoo,Anthony J. Olszanski,Olalekan O. Oluwole,Sandip Pravin Patel,Sunil Reddy,Mabel Ryder,Bianca Santomasso,Scott Shofer,Jeffrey A. Sosman,Momen M. Wahidi,Yinghong Wang,Alyse Johnson-Chilla,Jillian L. Scavone +30 more
TL;DR: The content featured in this issue is an excerpt of the recommendations for managing toxicity related to immune checkpoint blockade and a review of existing evidence.